India, Sept. 24 -- Addex Therapeutics (ADXN) is scheduled to report its second-quarter and first-half 2026 financial results on September 28, 2026, with investors likely to focus on the company's financial position, pipeline progress and developments surrounding its Neurosterix spin-out.
Addex is a clinical-stage biopharmaceutical company developing small molecule allosteric modulators for neurological disorders.
The company holds a 20% equity interest in Neurosterix US Holdings LLC, which is advancing programs including an M4 positive allosteric modulator for schizophrenia, psychosis and mood-related disorders.
First Quarter 2026 Results
In the first quarter of 2026, Addex reported a net loss of CHF 1.71 million, or CHF 0.01 per share,...